All Outputs (4)

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial (2023)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Francis, A., …Cook, J. A. (2023). Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial. The Lancet Rheumatology, 6(2), e92-e104. https://doi.org/10.1016/s2665-9913%2823%2900298-9

Background: Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improv... Read More about Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.

Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial (2023)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Francis, A., …Study investigators, V. (2024). Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial. The Lancet Rheumatology, 6(2), E92-E104. https://doi.org/10.1016/S2665-9913%2823%2900298-9

Background Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improv... Read More about Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial.

Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study (2023)
Journal Article
Hippisley-Cox, J., Khunti, K., Sheikh, A., Nguyen-Van-Tam, J. S., & Coupland, C. A. (2023). Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study. BMJ, 381, Article e072976. https://doi.org/10.1136/bmj-2022-072976

Objectives To derive and validate risk prediction algorithms (QCOVID4) to estimate the risk of covid-19 related death and hospital admission in people with a positive SARS-CoV-2 test result during the period when the omicron variant of the virus was... Read More about Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study.

Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD (2023)
Journal Article
Card, T. R., Nakafero, G., Grainge, M. J., Mallen, C. D., Van-Tam, J. S. N., Williams, H. C., & Abhishek, A. (2023). Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD. American Journal of Gastroenterology, 118(8), 1388-1394. https://doi.org/10.14309/ajg.0000000000002205

INTRODUCTION: To investigate the association between vaccination against coronavirus disease 2019 (COVID-19) and inflammatory bowel disease (IBD) flare. METHODS: Patients with IBD vaccinated against COVID-19 who consulted for disease flare be... Read More about Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD.